HOME >> BIOLOGY >> NEWS
Abgenix initiates phase III clinical trial of graft versus host disease therapy

Abgenix to Seek a Corporate Partner to Commercialize ABX-CBL

FREMONT, Calif., December 7, 1999 - Abgenix, Inc. (Nasdaq: ABGX) is initiating a Phase III clinical trial comparing its antibody, ABX-CBL, with standard therapy for patients with steroid-resistant graft-versus-host disease (srGVHD), a serious, life-threatening disorder. Abgenix also indicated that it would seek a corporate partner to assist with the development and commercialization of ABX-CBL.

Abgenix is pursuing the Phase III trial of ABX-CBL based on promising results of a 59 patient Phase II trial of the drug. In that trial, srGVHD patients receiving higher doses of ABX-CBL had more than twice the 180-day survival rate observed in the lowest dose cohort, according to results presented at the annual meeting of the American Society of Hematology (ASH). Survival at 180 days for patients in the higher dose cohorts was 50% versus 22% in the lowest (presumed no effect) dose cohort.

"ABX-CBL demonstrated important clinical benefits as measured by response rate and survival in the Phase II clinical trial," said H. Joachim Deeg, M.D., Department of Transplantation Biology at Fred Hutchinson Cancer Research Center and Principal Investigator for the trial. "Given the limited options available for treating srGVHD patients, ABX-CBL has the potential to be an important new treatment for this disease."

"While we are enthusiastic about ABX-CBL's potential as a much needed treatment for srGVHD, our business strategy is to find corporate partners to commercialize the products we generate," stated R. Scott Greer, president and CEO of Abgenix. "Therefore, we would like to identify a pharmaceutical or biotech company with the development and marketing infrastructure to maximize the commercial potential of ABX-CBL. We plan to begin the Phase III trial on our own, but would like to have a partner on board before it is completed."

GVHD occurs in
'"/>

Contact: Kurt Leutzinger, Abgenix, Inc.
510-608-6575
Porter Novelli
6-Dec-1999


Page: 1 2 3

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. Southern stroke belt study initiates nationwide study
8. Trans-NIH collaboration with NIOSH initiates studies of racial and ethnic disparities in health
9. Gulf of Maine marine ecosystem may have entered new phase
10. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
11. Psoriasis treatment based on Weizmann Institute Research passes phase II clinical trials

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2018)... ... September 24, 2018 , ... EDETEK, the premier ... exhibiting at the Society for Clinical Data Management (SCDM) 2018 Annual Conference taking ... participating at DPHARM: Disruptive Innovations in Boston, MA on September 25-26, 2018. ...
(Date:9/24/2018)... (PRWEB) , ... September 24, 2018 , ... ... requires the hepatitis B surface antigen (HBsAg) to infect the hepatocytes. Chronic Hepatitis ... accelerated progression of cirrhosis and hepatocellular carcinoma and a high mortality rate. ...
(Date:9/24/2018)... ... September 24, 2018 , ... Energetiq Technology, a world ... announce that starting on October 1, 2018 Hamamatsu will distribute the company’s Laser-Driven ... have been working steadfastly since our acquisition to integrate with Hamamatsu and familiarize ...
Breaking Biology News(10 mins):
(Date:9/12/2018)... ... September 12, 2018 , ... NDA ... professional and former Senior Director of Regulatory Affairs and Quality Systems at WellDoc, ... Director of Regulatory Affairs and Quality Systems at WellDoc, Inc., she conducted quality ...
(Date:9/7/2018)... ANN ARBOR, Mich. (PRWEB) , ... September 06, 2018 , ... ... of Directors. Dunbar has spent his career as an executive and leader of numerous ... Biologics, a private cell therapy and biologics company acquired by Thompson Street Capital in ...
(Date:8/29/2018)... ... ... Cognition Corporation ®, a software company specializing in medical device compliance ... , Ryan Ward, Director of Engineering at Zimmer Biomet, has been announced as a ... with Zimmer Biomet for almost 15 years, Mr. Ward will focus his talk about ...
(Date:8/26/2018)... ... August 23, 2018 , ... ... innovators, engineers, and scientists from around the world, will host the 4th Annual ... an array of industries and disciplines, encompassing various research areas including medicine, agriculture, ...
Breaking Biology Technology:
Cached News: